Essential role of formyl peptide receptor 1 in anthracycline-based anticancer chemotherapy

ABSTRACT: Tumor growth reduction induced by anthracycline-based chemotherapy is largely determined by an anticancer immune response that is ignited by the presentation of dead-cell antigens by intratumoral dendritic cells. In an unbiased screen designed to identify cancer therapy-relevant single nucleotide polymorphisms in genes affecting the interaction between dying tumor cells and immune cells, we identified a loss-of-function allele of the gene coding for formyl peptide receptor 1 (FPR1) that was associated with poor metastasis-free and overall survival in breast cancer patients receiving adjuvant chemotherapy. In mice, the therapeutic effects of anthracyclines were abrogated when the immune system was rendered deficient for FPR1 or when tumor cells lacked the FPR1 ligand Annexin A1 (ANXA1). Def

ORGANISM(S): Mus musculus

SUBMITTER: Joachim Schultze 

PROVIDER: E-GEOD-63410 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress